{
  "company": {
    "name": "Cybrexa Therapeutics",
    "website": "https://cybrexa.com/",
    "record": "https://startuphistory.org/c/cybrexa.com"
  },
  "status": null,
  "history_since": "2017-06-19T23:15:04.000Z",
  "baseline": {
    "snapshot_id": "088eb8d257b72d12eff79323225a54fa8a11d8e1cdca30b27f2dee6e21b8fb1a",
    "observed_at": "2017-06-19T23:15:04.000Z",
    "headline": "Cybrexa Therapeutics | Changing the paradigm of cancer drug delivery.",
    "description": "Changing the paradigm of cancer drug delivery.",
    "evidence": "https://web.archive.org/web/20170619231504/https://cybrexa.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-05T13:11:00.713Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2017-06-19T23:15:04.000Z",
      "variants": [
        {
          "headline": "Cybrexa Therapeutics | Changing the paradigm of cancer drug delivery.",
          "subhead": "Changing the paradigm of cancer drug delivery.",
          "observed_at": "2017-06-19T23:15:04.000Z",
          "evidence": "https://web.archive.org/web/20170619231504/https://cybrexa.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Cybrexa Therapeutics | Changing the paradigm of cancer drug delivery.",
      "subhead": "Changing the paradigm of cancer drug delivery.",
      "from": "2017-06-19T23:15:04.000Z",
      "to": "2017-06-19T23:15:04.000Z",
      "captures": 1,
      "evidence": "https://web.archive.org/web/20170619231504/https://cybrexa.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "on": "2017-06-19T23:15:04.000Z"
      },
      "current": false
    },
    {
      "quote_observed_at": "2018-01-18T15:24:26.000Z",
      "variants": [
        {
          "headline": "Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment.",
          "subhead": "Cybrexa Therapeutics is changing the paradigm of cancer drug delivery with tumor-localizing peptide technology. We are located near Yale in New Haven, CT.",
          "observed_at": "2018-01-18T15:24:26.000Z",
          "evidence": "https://web.archive.org/web/20180118152426/https://cybrexa.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment.",
      "subhead": "Cybrexa Therapeutics is changing the paradigm of cancer drug delivery with tumor-localizing peptide technology. We are located near Yale in New Haven, CT.",
      "from": "2018-01-18T15:24:26.000Z",
      "to": "2018-01-18T15:24:26.000Z",
      "captures": 1,
      "evidence": "https://web.archive.org/web/20180118152426/https://cybrexa.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "on": "2018-01-18T15:24:26.000Z"
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-05T13:11:00.713Z",
      "variants": [
        {
          "headline": "targeted intracellular delivery",
          "subhead": null,
          "observed_at": "2019-01-07T06:34:37.000Z",
          "evidence": "https://web.archive.org/web/20190107063437/http://www.cybrexa.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "targeted intracellular delivery",
          "subhead": null,
          "observed_at": "2020-02-21T20:18:36.000Z",
          "evidence": "https://web.archive.org/web/20200221201836/http://www.cybrexa.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "targeted intracellular delivery",
          "subhead": null,
          "observed_at": "2021-01-25T16:49:39.000Z",
          "evidence": "https://web.archive.org/web/20210125164939/http://www.cybrexa.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "targeted intracellular delivery",
          "subhead": null,
          "observed_at": "2022-01-11T05:58:47.000Z",
          "evidence": "https://web.archive.org/web/20220111055847/http://www.cybrexa.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "targeted intracellular delivery",
          "subhead": null,
          "observed_at": "2023-02-05T04:17:05.000Z",
          "evidence": "https://web.archive.org/web/20230205041705/http://www.cybrexa.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "targeted intracellular delivery",
          "subhead": null,
          "observed_at": "2024-01-04T15:29:12.000Z",
          "evidence": "https://web.archive.org/web/20240104152912/https://www.cybrexa.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "targeted intracellular delivery",
          "subhead": null,
          "observed_at": "2025-01-14T15:09:05.000Z",
          "evidence": "https://web.archive.org/web/20250114150905/https://www.cybrexa.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "targeted intracellular delivery",
          "subhead": null,
          "observed_at": "2025-08-03T05:15:31.000Z",
          "evidence": "https://web.archive.org/web/20250803051531/https://www.cybrexa.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "targeted intracellular delivery",
          "subhead": null,
          "observed_at": "2026-02-12T04:02:50.000Z",
          "evidence": "https://web.archive.org/web/20260212040250/https://www.cybrexa.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "targeted intracellular delivery",
          "subhead": null,
          "observed_at": "2026-06-18T17:50:43.000Z",
          "evidence": "https://web.archive.org/web/20260618175043/https://www.cybrexa.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "targeted intracellular delivery",
          "subhead": null,
          "observed_at": "2026-11-05T13:11:00.713Z",
          "evidence": "https://www.cybrexa.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "targeted intracellular delivery",
      "subhead": null,
      "from": "2019-01-07T06:34:37.000Z",
      "to": "2026-11-05T13:11:00.713Z",
      "captures": 11,
      "evidence": "https://www.cybrexa.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2019-01-07T06:34:37.000Z",
          "to": "2026-11-05T13:11:00.713Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-a00bf92bf995d93e507ad08e5747608a07fb5bb8b1db5a5e5c2fbe542533c78a:703b08b3d312d062836acdf62ef4b80b635d68d7941cffb50af98b5f02e48274:headline:59ef23c32a553581",
      "before_evidence": "https://web.archive.org/web/20180118152426/https://cybrexa.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvi…” to “targeted intracellular delivery”.",
      "between": {
        "from": "2018-01-18T15:24:26.000Z",
        "to": "2019-01-07T06:34:37.000Z"
      },
      "evidence": "https://web.archive.org/web/20190107063437/http://www.cybrexa.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Cybrexa Therapeutics” company record, https://startuphistory.org/c/cybrexa.com"
}